Enhanced Recovery after Fetal Sequencing: A Perinatal Genomic Scoping Review of Exome/Genome Testing for Reproductive/Obstetric-MFM Providers to Initiate Knowledge Translation following a Screening Ultrasound Identifying Fetal Anomalies
Fetal Diagnosis and Therapy · 2025
DOI: 10.1159/000546993 ↗Kurz gefasst
Scoping Review in der Zeitschrift Fetal Diagnosis and Therapy, 2025. Verfasst von Robert Douglas Wilson. Beteiligte Einrichtung: Department of Obstetrics and Gynecology and Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Genetic Testing, Ultrasonography, Prenatal, Exome Sequencing, Prenatal Diagnosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 92 Literaturangaben.
Themen: Evidenzbasierte Pflege
Abstract (Originalsprache)
Background: This review of genomic perinatal opportunities and uses will provide counseling and personal genetic knowledge for improved patient care. Summary: This focused systematic analysis and review has used PubMed keywords to identify genomic testing for ultrasound-identified fetal anomaly(ies) that require diagnostic testing after an informed consent process. Multiple fetal anomalies, using TRIO sequencing processes, have a better diagnostic yield, with certain cohorts >50%. For the single anatomic categories, skeletal system, central nervous system, and renal system, using WES fetal sequencing (most commonly) for a diagnostic result, have the larger incremental diagnostic yield over the chromosome micro-array. Key Messages: The phenotype-genotype (fetal-genomic result) consideration and use of the prenatal exome sequencing technology can be summarized using a SWOT analysis: strength (enhanced evaluation of fetal-neonatal genomic abnormalities not identified by standard chromosomal microarray and improved ethical care decisions); weakness (the understanding and complexity of genomic pathology and testing/the fiscal cost for professional time and the health system services); opportunity (an increased recognition of fetal genetic risk pathology [de novo or inherited carrier mutations] with improved understanding and knowledge translation of counseling for recurrence risk); threat (inability to provide a genetic diagnosis or interpret a variant of unknown significance or the discovery of incidental findings or unanticipated parental genomic diagnoses).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology and Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Zitieren
APA
Wilson, R. D. (2025). Enhanced Recovery after Fetal Sequencing: A Perinatal Genomic Scoping Review of Exome/Genome Testing for Reproductive/Obstetric-MFM Providers to Initiate Knowledge Translation following a Screening Ultrasound Identifying Fetal Anomalies. Fetal Diagnosis and Therapy. https://doi.org/10.1159/000546993
Vancouver
Wilson RD. Enhanced Recovery after Fetal Sequencing: A Perinatal Genomic Scoping Review of Exome/Genome Testing for Reproductive/Obstetric-MFM Providers to Initiate Knowledge Translation following a Screening Ultrasound Identifying Fetal Anomalies. Fetal Diagnosis and Therapy. 2025. doi:10.1159/000546993
BibTeX
@article{Wilson2025,
author = {Wilson, Robert Douglas},
title = {Enhanced Recovery after Fetal Sequencing: A Perinatal Genomic Scoping Review of Exome/Genome Testing for Reproductive/Obstetric-MFM Providers to Initiate Knowledge Translation following a Screening Ultrasound Identifying Fetal Anomalies},
journal = {Fetal Diagnosis and Therapy},
year = {2025},
doi = {10.1159/000546993}
}
EUVIMED